A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/6927639 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545464101109760 |
|---|---|
| author | Kathryn Fleming James McGuinness David Kipgen Hilary Glen Pavlina Spiliopoulou |
| author_facet | Kathryn Fleming James McGuinness David Kipgen Hilary Glen Pavlina Spiliopoulou |
| author_sort | Kathryn Fleming |
| collection | DOAJ |
| description | We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now. |
| format | Article |
| id | doaj-art-bce0a28a77c3435484c6451c858aa2e1 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-bce0a28a77c3435484c6451c858aa2e12025-02-03T07:25:50ZengWileyCase Reports in Oncological Medicine2090-67062090-67142018-01-01201810.1155/2018/69276396927639A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid CancerKathryn Fleming0James McGuinness1David Kipgen2Hilary Glen3Pavlina Spiliopoulou4Beatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UKBeatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UKQueen Elizabeth University Hospital, Glasgow, UKBeatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UKBeatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UKWe describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now.http://dx.doi.org/10.1155/2018/6927639 |
| spellingShingle | Kathryn Fleming James McGuinness David Kipgen Hilary Glen Pavlina Spiliopoulou A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer Case Reports in Oncological Medicine |
| title | A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer |
| title_full | A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer |
| title_fullStr | A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer |
| title_full_unstemmed | A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer |
| title_short | A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer |
| title_sort | case of lenvatinib induced focal segmental glomerulosclerosis fsgs in metastatic medullary thyroid cancer |
| url | http://dx.doi.org/10.1155/2018/6927639 |
| work_keys_str_mv | AT kathrynfleming acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT jamesmcguinness acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT davidkipgen acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT hilaryglen acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT pavlinaspiliopoulou acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT kathrynfleming caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT jamesmcguinness caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT davidkipgen caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT hilaryglen caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer AT pavlinaspiliopoulou caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer |